317 related articles for article (PubMed ID: 30777124)
21. Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
Kumar N; Alrifai D; Kolluri KK; Sage EK; Ishii Y; Guppy N; Borg E; Falzon M; Nankivell M; Nicholson AG; Janes SM
Lung Cancer; 2019 Jan; 127():164-166. PubMed ID: 30642545
[TBL] [Abstract][Full Text] [Related]
22. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
[TBL] [Abstract][Full Text] [Related]
24. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
25. [Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
[TBL] [Abstract][Full Text] [Related]
26. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
[TBL] [Abstract][Full Text] [Related]
27. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract][Full Text] [Related]
28. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
[TBL] [Abstract][Full Text] [Related]
29. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y
Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371
[TBL] [Abstract][Full Text] [Related]
30.
Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
[TBL] [Abstract][Full Text] [Related]
31. Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
Fels Elliott DR; Travieso JL; As-Sanie S; Hrycaj SM; Lieberman RW; Myers JL; Huang T
Int J Gynecol Pathol; 2022 Sep; 41(5):535-540. PubMed ID: 34723845
[TBL] [Abstract][Full Text] [Related]
32. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
33. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
34. BAP1 GERMLINE MUTATION WITH IRIDOCILIOCHOROIDAL MELANOMA AND MALIGNANT PERITONEAL MESOTHELIOMA.
Yaghy A; Lim LA; Mashayekhi A; Shields CL
Retin Cases Brief Rep; 2022 Mar; 16(2):194-198. PubMed ID: 31895725
[TBL] [Abstract][Full Text] [Related]
35. Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.
Taylor S; Carpentieri D; Williams J; Acosta J; Southard R
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e323-7. PubMed ID: 25222065
[TBL] [Abstract][Full Text] [Related]
36. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
[TBL] [Abstract][Full Text] [Related]
37. Tumours associated with BAP1 mutations.
Murali R; Wiesner T; Scolyer RA
Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
[TBL] [Abstract][Full Text] [Related]
38. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
[TBL] [Abstract][Full Text] [Related]
39. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
[TBL] [Abstract][Full Text] [Related]
40. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.
Ladanyi M; Zauderer MG; Krug LM; Ito T; McMillan R; Bott M; Giancotti F
Clin Cancer Res; 2012 Sep; 18(17):4485-90. PubMed ID: 22825583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
